BioNTech Sees Potential to Supply 3 Billion Doses in 2022 (1)

March 10, 2021, 8:15 AM

BioNTech SE could have capacity to make 3 billion doses of Covid-19 vaccine with U.S. partner Pfizer Inc. next year, the German company’s chief executive officer said, making their pioneering shot far more widely available around the world.

“In principle, we could further increase manufacturing capacity,” Ugur Sahin said Tuesday in an interview with Bloomberg TV. “It depends on demand, it depends on factors such as if an additional boost to vaccinations is required.”

WATCH: BioNTech CEO Ugur Sahin says the company is looking into partnerships to help produce the Covid-19 vaccine in higher quantities.
(Source: Bloomberg)

Demand is growing around the world for Covid vaccines that countries desperately need to breathe back life into economies, return children to schools and get ...

To read the full article log in.

Learn more about a Bloomberg Law subscription